These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 24668644)

  • 1. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
    Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
    Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
    Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
    Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection.
    Pan QZ; Zhao JJ; Yang CP; Zhou YQ; Lin JZ; Tang Y; Gu JM; Wang QJ; Li YQ; He J; Chen SP; Song MJ; Huang Y; Yang JY; Weng DS; Xia JC
    Oncoimmunology; 2020; 9(1):1752563. PubMed ID: 32363125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.
    Hui D; Qiang L; Jian W; Ti Z; Da-Lu K
    Dig Liver Dis; 2009 Jan; 41(1):36-41. PubMed ID: 18818130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer.
    Yang X; Weng D; Pan Q; Xiang T; Yang C; Wu Z; Li M; Xie S; Tang Y; Xia J; Zhao J
    Front Immunol; 2022; 13():974487. PubMed ID: 36439119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients.
    Zhao H; Fan Y; Li H; Yu J; Liu L; Cao S; Ren B; Yan F; Ren X
    Cancer Biother Radiopharm; 2013 May; 28(4):303-9. PubMed ID: 23506427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of two different immunotherapies on triple negative breast cancer in animal model.
    Liu X; Hu J; Cao W; Qu H; Wang Y; Ma Z; Li F
    Cell Immunol; 2013; 284(1-2):111-8. PubMed ID: 23973874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.
    Lin M; Liang S; Jiang F; Xu J; Zhu W; Qian W; Hu Y; Zhou Z; Chen J; Niu L; Xu K; Lv Y
    Immunol Lett; 2017 Mar; 183():37-43. PubMed ID: 28143792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution in management of patients with subcentimeter, node-negative, triple-negative breast cancer.
    Wolfe E; Corsetti R; Bolton JS; Stolier AJ; Fuhrman GM
    Am J Surg; 2013 Dec; 206(6):888-92; discussion 892-3. PubMed ID: 24112681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: A historical cohort study.
    Bhoo-Pathy N; Verkooijen HM; Wong FY; Pignol JP; Kwong A; Tan EY; Aishah Taib N; Nei WL; Ho GF; Tan B; Chan P; Lee SC; Hartman M; Yip CH; Dent R
    Int J Cancer; 2015 Nov; 137(10):2504-12. PubMed ID: 26018878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.
    Buyukhatipoglu H; Babacan T; Kertmen N; Balakan O; Suner A; Ates O; Sarici F; Aslan A; Diker O; Tasdemir V; Ozisik Y; Altundag K
    J BUON; 2015; 20(1):22-7. PubMed ID: 25778291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
    Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
    Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients.
    Zhang Y; Wang S; Yang B; Lu S; Du Y; Liu H
    Cancer Biol Med; 2019 May; 16(2):350-360. PubMed ID: 31516755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
    Zhou ZQ; Zhao JJ; Pan QZ; Chen CL; Liu Y; Tang Y; Zhu Q; Weng DS; Xia JC
    J Immunother Cancer; 2019 Aug; 7(1):228. PubMed ID: 31455411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.